Eleven Biotherapeutics, Inc. EBIO
— —
At closeJun 28, 2019, 6:07 PM EDT
Day range unavailable
52-week range unavailable
News
benzinga.com 40 Stocks Moving In Wednesday's Mid-Day Session 
businesswire.com Eleven Biotherapeutics Reports First Quarter Financial Results and
Pipeline Updates CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of…
businesswire.com Eleven Biotherapeutics to Report Third Quarter 2017 Financial Results
on November 14, 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics…
benzinga.com 45 Biggest Movers From Yesterday 
benzinga.com 40 Stocks Moving In Wednesday's Mid-Day Session 
benzinga.com Mid-Morning Market Update: Markets Open Higher; Estee Lauder Tops Q3 Expectations 
businesswire.com Eleven Biotherapeutics to Report Second Quarter 2017 Financial
Results on Monday, August 14, 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting…
businesswire.com Eleven Biotherapeutics to Report First Quarter 2017 Financial Results
on Thursday, May 4, 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting…
businesswire.com Eleven Biotherapeutics to Report Fourth Quarter and Full Year 2016
Financial Results on Friday, March 24, 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting…
businesswire.com Eleven Biotherapeutics to Report Third Quarter 2016 Financial Results
on November 14, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late stage clinical oncology company advancing a broad pipeline of novel product candidates based on a Targeting…
businesswire.com Eleven Biotherapeutics Acquires Viventia Bio to Create Targeted
Protein Therapeutics Oncology Company CAMBRIDGE, Mass. & TORONTO--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) and Viventia Bio Inc., today announced that the two companies and the shareholders of Viventia entered into a…
businesswire.com Eleven Biotherapeutics to Report Third Quarter 2015 Financial Results
on November 4, 2015 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the…
benzinga.com Morning Market Gainers 
businesswire.com Eleven Biotherapeutics to Report Second Quarter 2015 Financial
Results on August 13, 2015 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the…
businesswire.com Eleven Biotherapeutics Announces Top-Line Results from Pivotal Phase
3 Study of EBI-005 in Patients with Moderate to Severe Dry Eye Disease CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (Nasdaq:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye,…
businesswire.com Eleven Biotherapeutics to Report First Quarter 2015 Financial Results
on April 30, 2015 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye,…
businesswire.com Eleven Biotherapeutics to Report Fourth Quarter and Full Year 2014
Financial Results on March 4, 2015 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics (NASDAQ:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today…
businesswire.com Eleven Biotherapeutics Reports Third Quarter 2014 Financial Results CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye,…
businesswire.com Eleven Biotherapeutics to Report Third Quarter 2014 Financial Results
on November 13, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye,…
businesswire.com Eleven Biotherapeutics Announces Top-Line Results from Phase 2 Study
of EBI-005 in Patients with Moderate to Severe Allergic Conjunctivitis CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the…
businesswire.com Eleven Biotherapeutics to Report Second Quarter 2014 Financial
Results on August 13, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the…
businesswire.com Eleven Biotherapeutics to Report First Quarter 2014 Financial Results
on May 15, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the…